{"id":2597,"date":"2026-08-18T09:00:00","date_gmt":"2026-08-18T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2597"},"modified":"2026-08-18T19:31:32","modified_gmt":"2026-08-18T23:31:32","slug":"amylyxs-avexitide-hits-phase-iii-endpoint-for-post-bariatric-hypoglycemia","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2597","title":{"rendered":"Amylyx’s Avexitide Hits Phase III Endpoint for Post-Bariatric Hypoglycemia"},"content":{"rendered":"

Company:<\/strong> Amylyx Pharmaceuticals · Event Type:<\/strong> Phase III Topline Data · Product:<\/strong> Avexitide · Mechanism:<\/strong> GLP-1 Receptor Antagonist · Indication:<\/strong> Post-Bariatric Hypoglycemia · Announcement Date:<\/strong> August 18, 2026<\/p>\n

\"Amylyx's<\/p>\n

Summary<\/h4>\n

Amylyx reported that avexitide met the FDA-agreed primary endpoint in the 78-participant Phase III LUCIDITY trial for post-bariatric hypoglycemia following Roux-en-Y gastric bypass. Once-daily subcutaneous avexitide reduced the composite rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo through Week 16 (p=0.000003). All stated secondary hypoglycemia endpoints were also met. The company plans an NDA submission by year-end 2026. The result is clinically and regulatorily meaningful, but remains a sponsor-reported topline disclosure without absolute event rates, confidence intervals, subgroup results or a complete adverse-event table.<\/p>\n

What Happened<\/h4>\n

LUCIDITY randomized adults 3:2 to avexitide 90 mg subcutaneously once daily or placebo across 21 U.S. sites. The primary endpoint measured the composite frequency of clinically significant Level 2 and severe Level 3 hypoglycemic events. Secondary endpoints evaluated Level 2 events by self-monitored glucose, Level 2 events by continuous glucose monitoring and independently adjudicated Level 3 events.<\/p>\n

Amylyx stated that avexitide was generally well tolerated. Most adverse events were mild or moderate; no serious adverse event was attributed to treatment. The most frequent events were diarrhea, injection-site erythema and injection-site bruising. Weight did not change materially in either group. A 32-week open-label extension and an expanded-access program remain ongoing.<\/p>\n

Deep Analysis<\/h4>\n

Post-bariatric hypoglycemia is driven in part by exaggerated meal-stimulated GLP-1 signaling, excessive insulin secretion and rapid postprandial glucose decline. Avexitide is a competitive GLP-1 receptor antagonist. Its mechanism therefore inverts the agonist strategy used for obesity and diabetes: it aims to blunt pathological incretin amplification without broadly suppressing nutrient absorption or causing weight loss.<\/p>\n

The reported 55% relative event-rate reduction is compelling because the endpoint counts events that can cause neuroglycopenia, impaired cognition, loss of consciousness or seizures. However, relative reduction alone does not reveal baseline burden, absolute event avoidance, dispersion across participants or whether benefit is driven mostly by Level 2 events rather than the rarer Level 3 events. The 78-person sample can support a large treatment effect but is less informative for uncommon adverse events and heterogeneous bariatric populations.<\/p>\n

Regulatory risk now shifts from efficacy detection toward data completeness, manufacturing, chronic-use safety and the acceptability of a once-daily injectable regimen. Breakthrough Therapy and orphan designations can facilitate interaction with FDA but do not establish approval. Durability in the open-label extension and concordance between patient-observed events and CGM will shape the benefit-risk assessment.<\/p>\n

Competitive Displacement<\/h4>\n

There is no FDA-approved treatment specifically for post-bariatric hypoglycemia. Current management relies on dietary modification and off-label medicines, with procedural or surgical intervention in refractory cases. If approved, avexitide could become the first disease-directed therapy and establish GLP-1 receptor antagonism as a new endocrine treatment class. Commercial and clinical uptake will depend on diagnosis rates, payer recognition, injection burden, training, adherence and the breadth of the final label. Evidence limited to Roux-en-Y gastric bypass may not automatically extend to sleeve-gastrectomy-associated disease.<\/p>\n

Company and Product Background<\/h4>\n

Amylyx is developing therapies across endocrine and neurodegenerative diseases. Avexitide is a 31-amino-acid peptide antagonist of the GLP-1 receptor that was acquired through Amylyx’s 2025 acquisition of Eiger BioPharmaceuticals assets. It has also been studied in congenital hyperinsulinism. Post-bariatric hypoglycemia can emerge after altered gastrointestinal anatomy accelerates nutrient delivery and amplifies incretin signaling; excess insulin drives recurrent glucose nadirs after meals, with symptoms ranging from tremor and confusion to loss of consciousness and seizures.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n\n
Signal<\/th>\nVerified Evidence<\/th>\nCurrent Limit<\/th>\n<\/tr>\n<\/thead>\n
Primary efficacy<\/td>\n55% relative reduction in Level 2\/3 composite; p=0.000003<\/td>\nAbsolute rates, confidence interval and dispersion undisclosed<\/td>\n<\/tr>\n
Secondary efficacy<\/td>\nAll stated SMBG, CGM and adjudicated Level 3 endpoints met<\/td>\nEndpoint-specific effect sizes not released<\/td>\n<\/tr>\n
Safety<\/td>\nNo treatment-related serious adverse events; mostly mild\/moderate events<\/td>\nSmall trial limits rare-event characterization<\/td>\n<\/tr>\n
Regulatory timing<\/td>\nNDA planned by year-end 2026<\/td>\nSubmission and acceptance are future events<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> LUCIDITY provides sufficient pivotal evidence for a favorable FDA review and positions avexitide as the first approved PBH therapy, supported by a prespecified FDA-agreed endpoint, very strong statistical significance and consistency across secondary measures. This would be upgraded by a filed and accepted NDA, durable extension benefit and a label covering clinically important events.<\/p>\n

Bear case:<\/strong> The topline result is robust but the practical effect may be narrower than the headline suggests, given injectable daily dosing, an RYGB-only pivotal population and missing absolute event burden. This would be confirmed by modest absolute benefit or poor persistence.<\/p>\n

InSilens Take<\/h4>\n

This is a 4\/5 positive clinical signal. The direction is supported by a randomized pivotal win on an FDA-agreed endpoint rather than by company tone. Interpretation remains moderate until full event-rate, subgroup, safety and extension data are available. The specific evidence that matters next is absolute event reduction, the distribution of benefit across patients, long-term injection adherence, rare adverse events, NDA acceptance and the final scope of any approved label.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 — pivotal evidence in a condition with no approved therapy. Direction:<\/strong> Positive — randomized primary and all stated secondary endpoints met. Confidence in facts:<\/strong> High — detailed sponsor release and registered trial design agree. Confidence in interpretation:<\/strong> Moderate — full data and regulatory review remain pending.<\/p>\n","protected":false},"excerpt":{"rendered":"

Amylyx reported that avexitide met the FDA-agreed primary endpoint in the 78-participant Phase III LUCIDITY trial for post-bariatric hypoglycemia following Roux-en-Y gastric bypass. Once-daily subcutaneous avexitide reduced the composite rate of Level 2 and…<\/p>\n","protected":false},"author":1,"featured_media":2604,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[370,371,372],"class_list":["post-2597","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-amylyx-pharmaceuticals","tag-avexitide","tag-post-bariatric-hypoglycemia"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2597"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2597\/revisions"}],"predecessor-version":[{"id":2611,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2597\/revisions\/2611"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2604"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}